NDATOPICALCREAM
Approved
Jul 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
2/8 — Basic
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Metvixia is a topical cream formulation of methyl aminolevulinate hydrochloride, a photosensitizing agent used in photodynamic therapy (PDT). It is applied to skin lesions and activated by light exposure to generate reactive oxygen species that destroy abnormal cells. The drug is primarily indicated for actinic keratosis and other pre-malignant skin conditions.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team right-sizing and shift toward cost management and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
Started Apr 2020
125 enrolled
Keratosis, Actinic
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
Started Sep 2019
557 enrolled
Actinic Keratoses
Comparison of Mechanical Penetration Enhancers on Metvixia Skin Penetration
Started Feb 2014
10 enrolled
Healthy
Career Relevance
Working on Metvixia offers exposure to late-stage product management, market access strategy, and LOE transition planning in dermatology. Professionals should expect focus on profitability optimization, competitive defense, and generic readiness rather than growth expansion or innovation.
Worked on METVIXIA at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.